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Abstract 
Background: Respiratory complications are uncommon, but often life-threatening features of Plasmodium vivax 
malaria. This study aimed to estimate the prevalence and lethality associated with such complications among P. vivax 
malaria patients in a tertiary hospital in the Western Brazilian Amazon, and to identify variables associated with severe 
respiratory complications, intensive care need and death. Medical records from 2009 to 2016 were reviewed aiming to 
identify all patients diagnosed with P. vivax malaria and respiratory complications. Prevalence, lethality and risk factors 
associated with WHO defined respiratory complications, intensive care need and death were assessed.
Results: A total of 587 vivax malaria patients were hospitalized during the study period. Thirty (5.1%) developed 
respiratory complications. Thirteen (43.3%) developed severe respiratory complications, intensive care was required 
for 12 (40%) patients and 5 (16.6%) died. On admission, anaemia and thrombocytopaenia were common find-
ings, whereas fever was unusual. Patients presented different classes of parasitaemia and six were aparasitaemic on 
admission. Time to respiratory complications occurred after anti-malarials administration in 18 (60%) patients and 
progressed very rapidly. Seventeen patients (56.7%) had comorbidities and/or concomitant conditions, which were 
significantly associated to higher odds of developing severe respiratory complications, need for intensive care and 
death (p < 0.05).
Conclusion: Respiratory complications were shown to be associated with significant mortality in this population. 
Patients with comorbidities and/or concomitant conditions require special attention to avoid this potential life-threat-
ening complication.
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Background
Malaria remains a major public health problem in 
endemic countries. Despite advances in control and 
elimination strategies, recent estimates by the World 
Health Organization (WHO) highlight its high morbidity 
and mortality. While the majority of malaria deaths are 
attributed to Plasmodium falciparum, it is now widely 
accepted that Plasmodium vivax, the most geographically 
widespread human malaria parasite (~ 8.5 million annual 
cases) may also cause severe disease, associated with 
3000 annual deaths globally [1]. Despite clinical evidence 
of severity from the inoculation of essentially ‘non-severe’ 
P. vivax strains during malariotherapy studies during in 
the 1930s [2], the recognition of vivax associated sever-
ity and its associated multi-organ dysfunction is relatively 
new [3–8]. This historical lack of attention by the global 
community of malariologists may have hampered more 
effective policies against malaria. Factors associated with 
geographical dispersion of vivax infection are complex, 
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especially regarding the prevalence of severe syndromes 
and fatal disease [9], with those in lower and unstable 
transmission settings, as in the Americas, presenting 
a wider variety of organ dysfunctions [10]. Underlying 
conditions and comorbidities have long been perceived 
as having a negative impact on vivax malaria outcomes. 
An autopsy series conducted among confirmed vivax 
infected individuals revealed that 76% of them presented 
some type of underlying condition [6]. In that study, 41% 
had developed lung complications [6]. However, no clear 
information is available regarding the general epidemiol-
ogy, risk factors and prevalence of respiratory complica-
tions in vivax malaria, especially in the Brazilian Amazon.
A recent meta-analysis showed that the prevalence of 
acute respiratory distress syndrome (ARDS) among vivax 
malaria cases ranged between 2.2% (adults) and 2.8% 
(children), with nearly 50% mortality, confirming the sig-
nificance and associated poor prognosis of this type of 
complication among P. vivax malaria patients [11]. More-
over, female sex, having any comorbidity, lower body 
temperature, lower haemoglobin, and low oxygen satu-
ration values (hypoxaemia) were significantly associated 
with mortality. However, as only studies containing res-
piratory complications were included, the prevalence of 
respiratory complications may have been overestimated. 
Similarly, population-based studies are rarely reported in 
the literature, leading to a possible publication bias. The 
aims of this study were to estimate the prevalence and 
lethality of such complications among P. vivax malaria 
patients in the Western Brazilian Amazon and to iden-
tify variables associated with the development of severe 
respiratory complications according to WHO definitions, 
need for intensive care (ICU) and death.
Methods
Study site and case management
The Fundação de Medicina Tropical Doutor Heitor Vieira 
Dourado (FMT-HVD) is a tertiary care centre in Manaus 
(Western Brazilian Amazon) and a reference institution 
for infectious diseases in the north region of the coun-
try. Patients may either directly seek care at the hos-
pital’s outpatient clinic or be referred from other local 
hospitals and surrounding municipalities. At hospital 
presentation, patients with fever, or history of fever in 
the preceding days, are tested for malaria by thick blood 
smear. Admission/arrival to the hospital may happen 
after microscopic diagnosis and treatment initiation at 
primary level of health-care. Patient data are registered 
in the hospital’s electronical medical charts  (iDoctor®). 
Once at the hospital, all patients undergo medical con-
sultation and a 7-day post treatment initiation follow-up 
visit if diagnosed with malaria. Patients presenting with 
any severe clinical sign according to WHO severe malaria 
definitions (impaired consciousness, jaundice, signifi-
cant bleeding, shock, respiratory distress and others) 
[12] are immediately referred to the emergency depart-
ment and managed accordingly. Additional investigation 
for concomitant infections is triggered by the presence 
of specific manifestations and/or at medical’s discre-
tion through clinical investigation and routine blood and 
urine testing. Comorbidities are sought based on patient’s 
provided information and medical chart assessment. 
G6PD deficiency is not tested systematically.
Malaria diagnosis and treatment
In Brazil, thick blood smears are routinely performed for 
malaria diagnosis and occur at different health posts in 
the primary level of health care. All malaria tests (posi-
tive and negative) are recorded in the national epide-
miological surveillance system for malaria (SIVEP), 
implemented by the Brazilian National Ministry of 
Health in 2002. Slides are read by local microscopists and 
results are given following a semi-quantitative system: 
1/2 + (200–300 parasites/mm3); 1 + (301–500 parasites/
mm3); 2  +  (501–10,000  parasites/mm3); 3  +  (10,001–
100,000  parasites/mm3); and 4  +  (>  100,001  parasites/
mm3). All positive slides and 10% of negative slides are 
routinely reviewed in a reference unit by senior micros-
copists. In case of divergence, the reviewed reading is 
updated in the SIVEP system. PCR diagnosis is not rou-
tinely performed for malaria diagnosis. Treatment is only 
provided after a positive smear for malaria. Anti-malarial 
treatment for P. vivax malaria occurs following WHO 
recommendations and Brazilian guidelines with chloro-
quine (CQ, 25  mg/kg divided in 3  days) for uncompli-
cated cases, or parenteral artemether or artesunate in 
patients suspected of severe malaria or severe vomiting, 
followed by primaquine (PQ, 3.5 mg/kg in 7 or 14 days) 
[13, 14].
Study design, population and data collection
A retrospective search of charts was performed using the 
International Classification of Diseases aiming to iden-
tify all patients diagnosed with P. vivax malaria who were 
hospitalized. After identification, all were completely 
screened for respiratory complications prior to hospi-
tal presentation, upon admission or during hospitaliza-
tion. These included respiratory complaints reported by 
the patient in the previous days to hospital presentation 
or at hospital presentation or by medical examination at 
admission or during the hospitalization period. All clini-
cal and laboratory information was then retrieved from 
the patient’s medical chart using a structured question-
naire completed by two independent investigators of 
the study. Data regarding parasitaemia, time of diagno-
sis, time of treatment start and anti-malarials used were 
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also collected if available. Fever data (axillary tempera-
ture  >  37.5  °C) was also collected if available. Patients 
anonymity was preserved through the analysis. No 
restriction of age was applied.
Respiratory complications and case definition
Respiratory distress (RD) was defined as the following: 
respiratory rate > 30/min and oxygen saturation < 92% 
on room air in adults [12] or respiratory rate > 40/min 
(children 12  months up to 5  years) or  >  50/min (chil-
dren aged from 2 to 12  months) and oxygen satura-
tion  <  90% [15]. Blood gas analysis was also used to 
further assist diagnosis and management when avail-
able. Both vivax and falciparum malaria share the same 
criteria for severe disease with exclusion of parasitae-
mia thresholds [12]. Severe WHO definitions for severe 
respiratory impairment in malaria, including acidotic 
breathing and pulmonary oedema (PE) were used [12]. 
Acute respiratory distress syndrome (ARDS) following 
Berlin definition was also used [16]. Definitions are pre-
sented in Table 1.
Statistical analysis
Statistical analyses were performed using independent t 
tests, Wilcoxon Mann–Whitney or χ2 tests to compare 
variables across groups stratified by three independent 
outcomes (development of severe respiratory impair-
ment composed by patients presenting PE and/or ARDS; 
patients in need for intensive care support and those 
who died). Difference in proportions were tested by Chi 
squared test (corrected by Fisher’s test if necessary). 
Odds ratio (OR) with its 95% confidence interval (CI) 
was calculated for association between variables and out-
comes using logistic regression. The diagnostic perfor-
mance of laboratorial parameters for the three outcomes 
was assessed by means of receiver operating characteris-
tic (ROC) curves. Significance was set as p < 0.05. Anal-
yses were performed using STATA version 12.1 (Stata 
Corp LP, Texas USA). The Strengthening the Reporting 
of Observational Studies in Epidemiology (STROBE) 
statement was used as guidelines for reporting this study 
(Additional file 1) [17].
Ethical considerations
This study was approved by the Ethics Review Board 
(ERB) of FMT-HVD, Manaus, Brazil (1943/2008) and 
the National Brazilian Committee of Ethics (CONEP) 
(343/2009). All data analysed were anonymous. Since 
data was obtained exclusively from the medical charts, 
the ERB gave a waiver of informed consent.
Results
Prevalence and lethality of respiratory complications
From 2009 to 2016, 25,225 cases were diagnosed with 
malaria in the FMT-HVD, of which 24,225 (96%) were 
positive for P. vivax. A total of 587 P. vivax malaria 
patients were hospitalized. Of these, 30 (5.1%) were 
documented to have respiratory complications. Overall 
prevalence of respiratory complications was 0.1% among 
all vivax malaria episodes in this period. Prevalence of 
severe respiratory complications among hospitalized 
patients was 43.3% (13 patients). Twelve (40%) needed 
intensive care management and 5 patients (16.6%) died 
(Fig. 1).
Table 1 Definitions used for respiratory complications associated to severe malaria
ARDS acute respiratory distress syndrome, FiO2 fraction of inspired oxygen, IQR inter-quartile range, PaO2 arterial partial pressure of oxygen, PEEP positive end-
expiratory pressure
Author, year (References) Name Definition
WHO 2014 [12] Severe malaria Respiratory distress Rapid, deep and labored breathing (severe acidosis)
 Mild—sustained nasal flaring and/or mild intercostal indrawing (recession)
 Severe—the presence of either marked indrawing (recession) of the bony structure of 
the lower chest wall or deep (acidotic) breathing
Pulmonary oedema Radiologically confirmed, or oxygen saturation < 92% on room air 
with a respiratory rate > 30/min, often with chest indrawing and diffuse wheeze or 
crepitation on pulmonary auscultation
ARDS Definition Task Force 
2012 [16]
Acute respiratory distress syn-
drome: the Berlin definition
Timing Within 1 week of a known clinical insult or new or worsening respiratory 
symptoms
Chest imaging (chest radiograph or computed tomography scan) Bilateral opacities—not 
fully explained by effusions, lobar/lung collapse, or nodules
Origin of oedema Respiratory failure not fully explained by cardiac failure or fluid 
overload. Need objective assessment (e.g., echocardiography) to exclude hydrostatic 
edema if no risk factor present
Oxygenation
 Mild:  PaO2/FiO2 200—300 mmHg with PEEP or CPAP ≥ 5 cm  H2O
 Moderate:  PaO2/FiO2 100—200 mmHg with PEEP ≥ 5 cm  H2O
 Severe:  PaO2/FiO2 ≤ 100 mmHg with PEEP ≥ 5 cm  H2O
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General characteristics of patients with respiratory 
complications
Epidemiological and clinical characteristics, treatments, 
parasitaemia, disease progression and outcome of all 
30 cases are summarized in Table  2. Summary data is 
presented in Table  3. Seventeen (56.6%) patients pre-
sented previous history of malaria infections. Twenty-
six (80%) patients received CQ for malaria treatment, 
with PQ association in 21 (70%). Fifteen (50%) patients 
had started anti-malarial treatment before hospitali-
zation. Eighteen patients (60%) developed respira-
tory complications after anti-malarial start. Seventeen 
(56.6%) presented comorbidities (diabetes mellitus type 
2, systemic hypertension, myasthenia gravis) and/or 
co-infections (HIV, Pseudomonas aeruginosa and Strep-
tococcus pneumoniae bacteremia, detected by blood 
analysis). Two female patients were pregnant (Table  2). 
Patients with comorbidities were older than those with-
out such conditions (45.8 ± 18.4 vs 23.7 ± 17.4, respec-
tively; p = 0.006). G6PD deficiency was suspected after 
severe haemolysis associated to history of PQ treat-
ment and was further confirmed in 5 (16.6%) patients. 
Haemodialysis was necessary in 5 (16.6%) patients 
(Table  2). Anaemia and thrombocytopaenia were com-
mon laboratory findings on admission exams (Table 2). 
Eleven (36.6%) patients had some degree of multi-organ 
involvement: 5 (16.6%) patients presented haemoglo-
bin < 7 g/dL, four (13.3%) presented creatinine > 3 mg/
dL, six (10%) presented impaired consciousness, five 
presented shock (16.6%) and 1 (3.3%) presented hypo-
glycemia (Table  2). Fifteen patients presented platelet 
count below 50,000/mm3; 12 presented platelet counts 
between  >  50,000 and  ≤  150,000/mm3 and three with 
platelet count > 150,000/mm3 (Table 2).
Parasitaemia
Twelve patients (40%) reported having started anti-
malarial treatment before hospital presentation due to 
positive malaria diagnosis in the previous days. A total 
of 6 patients (20%) were already aparasitaemic at hospital 
admission, 5 (16.6%) patients presented one cross parasi-
taemia, 11 (36.7%) presented 2 crosses and 8 (26.7%) pre-
sented 3 crosses.
Severe respiratory complications
Of the 30 patients with a respiratory complication, 13 
(43.3%) patients developed severe respiratory complica-
tions (PE and/or ARDS). The proportion of patients pre-
senting comorbidities and/or concomitant conditions 
was significantly increased in this group (p  =  0.001). 
Four patients died. Lung deterioration occurred after 
anti-malarials in nine patients (69.2%) of this group and 
progressed rapidly in some cases. Further results are pre-
sented in Table 3. Radiological findings (including alveo-
lar infiltrates and diffuse patchy bilateral opacities) of 
three cases developing ARDS are presented Fig. 2.
Fig. 1 Study flow chart. Patients with Plasmodium vivax malaria developing respiratory complications between 2009 and 2016
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Comorbidities and concomitant conditions [OR 9.2 
(95% CI 1.3–113.2); p  =  0.017] and having initiated 
anti-malarial treatment before hospitalization [OR 7.3 
(95% 1.2–60.9); p = 0.025] were associated with higher 
odds of developing severe respiratory complications. 
Previous malaria infections, haemoglobin, platelets, 
leucocytes and other variables were not associated to 
developing severe respiratory complications in these 
patients. Complete results of univariate analysis for 
risk factors and development of severe respiratory 
complications are presented in Additional file 2: Table 
S1.
ROC analysis was performed in order to depict the 
discriminatory performance of laboratory variables for 
patients developing severe respiratory complications. 
Platelets [AUC 0.783 (95% CI 0.608–0.958), cut point 
66000 (78.8% sensitivity; 82.3% specificity)] and leuco-
cytes [AUC 0.781 (95% CI 0.607–0.954)] presented with 
reasonable discriminative performance for developing 
severe respiratory complications (Additional file 5: Table 
S4).
Intensive care and death
Twelve (40%) patients needed intensive care support. 
Analysis revealed that these patients presented comor-
bidities and/or concomitant conditions (33.3% vs 91.6%, 
p = 0.002) more frequently and had lower haemoglobin 
values at admission (10.2 ±  0.4  g/dL vs 8.5 ±  0.6  g/dL, 
p = 0.003). Also, creatinine and urea at admission were 
found to be significantly elevated in this group, with four 
(33.3%, p = 0.046) patients requiring further haemodialy-
sis (Table 4).
The group composed by patients who died (n  =  5, 
16.6%) was older (32 ±  4 vs 54 ±  8, p =  0.042). Preva-
lence of comorbidities and/or concomitant conditions 
was significant (48% vs 100%, p = 0.032). Lower levels of 
haemoglobin (p = 0.037), higher levels of urea (p = 0034) 
and lactate dehydrogenase enzyme (p  <  0.001) and also 
a higher proportion of patients (three, 60%, p =  0.004) 
requiring haemodialysis was observed. Results are pre-
sented in Table 4.
Comorbidities and/or concomitant conditions [OR 
19.6 (95% CI 2–1023); p  =  0.003] and creatinine [OR 
Table 3 Demographics and baseline characteristics between patients with severe and non-severe respiratory complica-
tions
Completeness of data: a 80%; b 96.6%; c 83%; d 73%; e 63.3%. Values expressed in mean (± standard error) unless stated otherwise. T-test or Wilkoxon–Mann–Whitney 
according to normality were used. Pearson Chi squared test was used to compare proportions. Significant if p < 0.05
GGT gama glutamil transferase, AST aspartate aminotransferase, ALT alanine aminotransferase
Variable All (n = 30) Severe respiratory complications
No (n = 17) Yes (n = 13) p value
Age in years (mean ± SE) 36.3 (± 3.8) 28.9 (± 4.5) 45.9 (± 5.8) 0.013
Sex (m/f ) 12/18 6/11 6/7 0.711
Comorbidities and concomitant conditions (n/%) 17 (56.7) 6 (35.3) 11 (84.6) 0.001
Respiratory symptoms at hospital admission (n/%) 23 (76.7) 12 (70.6) 11 (84.6) 0.427
Time of previous symptoms (days—mean ± SE) 6 (± 0.6) 6.7 (± 0.8) 5.1 (± 0.9) 0.899
Fever on admission (n/%) 12 (40) 9 (52.9) 3 (23.1) 0.141
First malaria episode (n/%)a 7 (23.3) 3 (17.6) 4 (30.7) 0.324
Respiratory complications after anti-malarials (n/%) 18 (60) 9 (52.9) 9 (69.2) 0.465
Anti-malarial treatment before hospitalization (n/%) 15 (50) 5 (29.4) 10 (76.9) 0.025
Patients requiring haemodialysis (n/%) 5 (16.7) 1 (5.9) 4 (30.7) 0.138
Death (n/%) 5 (16.6) 1 (5.9) 4 (30.7) 0.138
Haemoglobin (g/dL) (mean ± SE) 9.6 (± 0.4) 9.9 (± 0.5) 9.1 (± 0.6) 0.857
Leucocytes (× 103/mm3) median (IQR) 6.5 (4.4–10.8) 5.3 (3.7–9.5) 8 (6.5–12.8) 0.042
Platelet count (× 103/mm3) median (IQR) 49.5 (31–91) 36 (28–51) 79 (66–101) 0.016
Creatinine (mg/dL) median (IQR)b 1 (0.8–1.5) 0.9 (0.7–1.2) 1 (0.9–2.3) 0.280
Urea (mg/dL) median (IQR)b 31 (24–69) 31 (23–42) 41 (24–88) 0.442
Bilirubin (mg/dL) median (IQR)c 1.6 (0.7–4.7) 2.2 (0.5–3.6) 0.9 (0.7–10) 0.978
Lactate dehydrogenase (U/L) (mean ± SE)d 911.7 (± 91.2) 809.2 (± 86.4) 1034.6 (± 169) 0.113
AST (U/L) median (IQR) 50 (31–59) 50 (29–57) 50 (35–94) 0.583
ALT(U/L) median (IQR) 31 (25–60) 31 (35–66) 32 (25–54) 0.952
GGT (U/L) median (IQR) 107 (53–192) 75 (52–128) 141 (71–217) 0.198
Alkaline Phosphatase (U/L) (mean ± SE)e 384 (± 53) 329 (± 50) 501 (± 125) 0.071
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3.4 (95%1.2–13.3); p  =  0.009 were significantly associ-
ated with higher odds for intensive care need (complete 
results are presented in Additional file 3: Table S2). Hae-
modialysis [OR 14.5 (95% CI 1–289.7); p  =  0.021] was 
significantly associated to higher odds of death (complete 
results are presented in Additional file 4: Table S3).
Receiver operating curve analysis was performed in 
order to depict the discriminatory performance of base-
line laboratory variables for patients that needed inten-
sive care and for those who died. Results from ROC 
analysis for intensive care need outcome showed that 
urea [AUC 0.81 (95% CI 0.63–0.959), cut point 45 (66.7% 
sensitivity; 94.1% specificity)] and creatinine [AUC 0.74 
(95% CI 0.54–0.95), cut point 1.5 (58.3% sensitivity; 
94.1% specificity)] presented reasonable discriminative 
performance for this outcome. When stratification was 
performed for final outcome (patients discharged alive 
or those who died), lactate dehydrogenase [AUC 0.88 
(95% CI 0.64–1), cut point 1389 (55% sensitivity; 100% 
specificity)] and bilirubin [AUC 0.81 (95% CI 0.43–1), cut 
point 12.7 (75% sensitivity; 100% specificity)] presented 
reasonable discriminative performance. Results are pre-
sented in Additional file 5: Table S4.
Discussion
Data from medical charts of 30 cases of hospitalized 
vivax malaria patients that developed respiratory com-
plications in a tropical disease hospital of the western 
Brazilian amazon, between 2009 and 2016, were col-
lected retrospectively. Anaemia and thrombocytopae-
nia at admission were common findings among these 
patients. Comorbidities and/or concomitant conditions 
Fig. 2 Radiological findings of three patients with P. vivax malaria who developed ARDS. A Progressed with acute renal failure, severe anaemia, 
disseminated intravascular coagulation and coma. Arrived intubated (D0), blood transfusion (D2), convulsions (D12), haemodialysis (D13) and died 
(D14). B Progressed with acute renal failure, hyperbilirubinemia and shock. Hospitalization (D0), intubated (D8) and discharged (D28). C G6PD defi-
cient (acute haemolysis after PQ). Progressed with shock and died in the following 24 h
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were present in more than half of the studied popula-
tion. Severe WHO defined respiratory complications and 
multi-organ failure developed in several cases with inten-
sive care being necessary. Reported anti-malarial regimen 
consisted mainly of CQ plus PQ with a more than half of 
patients developing respiratory complications after treat-
ment start.
A pooled analysis of clinical studies since the year 
1900 describing complications in vivax patients showed 
a 0.27% prevalence of respiratory dysfunction in reports 
with and without severity signs [10]. Geographical strati-
fication has shown that prevalence estimates of respira-
tory complications vary according to endemic regions 
[11], mostly due to a complex interplay of host and vector 
characteristics [9]. Nonetheless, part of the variation is 
because of definitions used to describe these respiratory 
complications. In the present study, prevalence of ARDS 
and other severe respiratory complications were found 
to be equivalent to studies of similar design originating 
from India [18–21] and other countries from South-East 
Asia, the Eastern Mediterranean and the Western-Pacific 
regions [22–26].
The presence of comorbidities and concomitant con-
ditions and the extent they contribute to complicated 
disease and death in malaria has lingered for centuries 
and still remains a matter of debate. A recent study from 
India with 511 P. vivax patients showed no significant 
difference in the presence of non-infectious comorbidi-
ties between severe and non-severe patients [27]. On the 
other hand, a study conducted in India and Brazil with 
778 patients showed that patients with comorbidities 
may present higher risk of complications and death [8]. 
Also, four out of seven patients with respiratory compli-
cations presented comorbidities in the Brazilian autopsy 
series [6]. Despite evidence of association between 
comorbidities and severe disease, this still needs elucida-
tion in vivax malaria. It is hypothesized that comorbidi-
ties, co-infections and other concomitant conditions may 
become unstable due to anaemia and fever in acute vivax 
infections. Thus, a concurrent acute or chronic relatively 
controlled condition can lead to a severe and potentially 
life-threatening one through hypoxia exacerbation and 
haemodynamic decompensation [28].
Table 4 Comparison of demographics and baseline characteristics between groups of patients in intensive care need 
and death outcome
Completeness of data: a 80%; b 96.6%; c 83%; d 73%; e 63.3%. Values expressed in mean (± standard error) unless stated otherwise. T-test or Wilkoxon–Mann–Whitney 
according to normality were used. Pearson Chi squared test was used to compare proportions. Significant if p < 0.05
GGT gama glutamil transferase, AST aspartate aminotransferase, ALT alanine aminotransferase
Variable Intensive care unit Final outcome
No (n = 18) Yes (n = 12) p-value Discharged alive (n = 25) Death (n = 5) p-value
Age in years (mean ± SE) 30.4 (± 4.3) 45 (± 6.4) 0.060 32.8 (± 4) 53.6 (± 7.7) 0.042
Sex (m/f ) 10/8 7/5 0.880 13/12 4/1 0.249
Comorbidities and concomitant conds. (n/%) 6 (33.3) 11 (91.6) 0.002 12 (48) 5 (100) 0.032
Resp. symptoms at hospital admission (n/%) 13 (72.2) 10 (83.3) 0.481 18 (72) 5 (100) 0.177
Time of previous symptoms (days—mean ± SE) 5.4 (± 0.7) 6.2 (± 1.1) 0.501 5.6 (± 0.7) 6.2 (± 1.3) 0.740
Fever on admission (n/%) 8 (44.4) 4 (33.3) 0.543 10 (40) 2 (50) 0.315
First malaria episode (n/%)a 4 (30.7) 3 (27.2) 0.851 5 (25) 2 (50) 0.231
Resp. complications after anti-malarials (n/%) 13 (72.2) 10 (83.3) 0.481 18 (72) 5 (100) 0.177
Anti-malarial treatment before hospitalization (n/%) 7 (38.9) 8 (66.6) 0.264 12 (48) 3 (60) 1
Patients requiring haemodialysis (n/%) 1 (5.5) 4 (33.3) 0.046 2 (8) 3 (60) 0.004
Haemoglobin (g/dL) (mean ± SE) 10.2 (± 0.4) 8.5 (± 0.6) 0.003 9.9 (± 0.4) 7.7 (± 0.7) 0.037
Leucocytes (× 103/mm3) median (IQR) 6.1 (3.9–9.5) 8.8 (6.1–17) 0.082 6.5 (4.4–9.9) 9.7 (5.7–32) 0.388
Platelet count (× 103/mm3) median (IQR) 40 (30–75) 80 (39.5–96) 0.211 45 (30–91) 81 (79–81) 0.231
Creatinine (mg/dL) median (IQR)b 0.9 (0.7–1) 1.8 (0.9–3) 0.024 1 (0.7–1.2) 2.3 (0.9–3) 0.368
Urea (mg/dL) median (IQR)b 28 (21–35) 70 (36–1555) 0.004 30 (22–44) 88 (41–194) 0.034
Bilirubin (mg/dL) median (IQR)c 1.6 (0.5–3.5) 3.5 (1–12) 0.149 1.6 (0.7–3.5) 19.8 (6.7–36) 0.053
Lactate dehydrogenase (U/L) (mean ± SE)d 785.8 (± 60) 1093 (± 196) 0.098 762 (± 72) 1420 (± 194) < 0.001
AST (U/L) median (IQR) 51 (31–58) 47 (31.5–84) 0.964 50 (33–58) 38 (28–74) 0.930
ALT(U/L) median (IQR) 41.5 (26–69) 28 (23.5–31) 0.111 38 (27–66) 25 (22–31) 0.221
GGT (U/L) median (IQR) 84 (52–259) 131 (71–142) 0.791 124 (53–192) 71 (61–140) 0.906
Alkaline Phosphatase (U/L) (mean ± SE)e 378 (± 54) 400 (± 149) 0.861 392 (± 60) 315 (± 15) 0.674
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G6PDd screening is not routinely performed in the 
Americas for vivax malaria placing this population at a 
high risk for haemolysis [29]. In the present study, five 
patients were screened for G6PD activity according to 
medical discretion. Due to this, G6PD status is unknown 
in the other patients. The precise pathogenic mechanisms 
involving G6PD deficiency, primaquine-induced haemol-
ysis and the development of respiratory complications in 
vivax malaria deserves more research and elucidation.
Several studies have reported cases of respiratory com-
plications in vivax malaria after treatment [11], with a 
tenfold increase in the risk for developing respiratory 
distress [8]. It is suggested that a post-treatment inflam-
matory phenomenon occurs within lung microvascula-
ture in these cases leading to respiratory impairment [30, 
31]. This study has shown a possible association between 
treatment initiation and respiratory impairment. Impor-
tantly, chloroquine is known to have immune-modula-
tory proprieties [32–34], which could further prevent 
worsening of post-treatment inflammation and associ-
ated symptoms. Nonetheless, after taking into account 
increasing chloroquine-resistance, a change to arte-
misinin combination therapies for Plasmodium blood 
stage killing, which does not have an anti-inflammatory 
profile, could further increase the number of post-treat-
ment inflammatory complications in vivax patients, such 
as respiratory distress [35]. Studies addressing this spe-
cific aspect of anti-malarial treatment switch are urgently 
needed.
The few published histopathological analyses in vivax 
malaria have revealed infiltrates of monocytes, lympho-
cytes, and neutrophils in pulmonary microvasculature 
along with phagocytosed pigment and diffuse alveolar 
damage [36, 37] and hyaline membrane formation [38]. 
Severe alveolar oedema and congestion with infiltrates 
containing mononuclear cells and suggestive images of 
adhesion of Plasmodium-infected red cells to lung micro-
vasculature have also been reported [39]. In P. vivax 
malaria, cytoadhesion of parasitized red blood cells also 
seems to occur, but to a much lesser extent and magni-
tude to what can be seen in P. falciparum [40, 41]. Addi-
tionally, peripheral parasitaemia is generally much lower 
in this species, due to the preferential invasion of reticu-
locytes [38]. Instead the relatively much greater inflam-
matory and endothelial activation, as revealed by elevated 
cytokines and other inflammatory-inducing molecules 
[42–44], may be responsible for alveolar-capillary barrier 
loss and increased permeability [38], and is probably the 
basis for the particular respiratory complications in this 
species, as seen here.
This study has limitations that need to be addressed. 
The authors decided to focus on respiratory com-
plications of P. vivax malaria and provide a more 
comprehensive description of its associated clinical 
manifestations in detriment of comparing epidemiologi-
cal, clinical and laboratory aspects between this type of 
complication and other WHO-defined severe malaria 
syndromes. Therefore, no risk factor for developing res-
piratory complications in comparison to other malaria 
related complications were assessed. The retrospective 
nature of this study accounts for incomplete data collec-
tion due to a lack of prospective and detailed targeted 
investigation, including proper registration of respira-
tory rates, which may lead to underestimation of the 
prevalence of this complication, accurate registration 
of oxygenation rates and mechanical ventilation param-
eters, which may lead to lack of proper classification of 
ARDS according to the Berlin definition and also proper 
malaria diagnosis through molecular methods and sys-
tematic co-infection screening and comorbidity investi-
gation. The decision to admit patients was made at the 
attending physician’s discretion and may have resulted in 
selection bias, which was minimized through adoption of 
WHO severe malaria criteria. A great number of patients 
in this study had received anti-malarial treatment prior 
to hospital presentation with some of them presenting 
aparasitaemic, or probably with declining parasitaemia, 
at the time of admission. This could implicate in clinical 
improvement at this time and may have underestimated 
the rate of respiratory complication. In addition, the 
relatively low prevalence of respiratory complications, 
and therefore, the small sample size in this study does 
not support more robust predictive analyses, which may 
further hamper translational implications. Furthermore, 
pathogenic mechanisms of respiratory deterioration 
development could not be explored with such a study 
design.
Conclusions
Respiratory complications were found to have low prev-
alence among all vivax episodes in this study. Despite 
that, this complication was found to be a frequent clini-
cal exacerbation among P. vivax malaria cases in need for 
hospital care. Comorbidities and/or concomitant condi-
tions occurred in older patients, were associated with 
worsening of cases and remained associated to elevated 
odds for severe respiratory complication development, 
intensive care need and death. In this case, age may have 
influenced the presence of comorbidities, and therefore, 
be associated to poor outcome. Nonetheless, the pres-
ence of comorbidities, but not age, directly influenced 
the poor outcome in this study. The results from this 
study points to the importance of properly recognizing 
the existence of complications in vivax malaria infec-
tion, especially in patients with associated comorbidities 
and/or concomitant conditions, and further supports 
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rebutting the old paradigm that it does not cause impor-
tant and lethal disease. Prospective studies are needed to 
better address this potentially dangerous clinical compli-
cation and the association between chronic, non-infec-
tious and infectious comorbidities, severe and fatal P. 
vivax infections.
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